ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXBiotechnology
+$0.13 today
- Market cap
- $1.42B
- Beta
- 0.00
Volume 0.65M
Average 1.06M
ADRX Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Accounts Payables history
Currency unavailable · from the cash flow
No Accounts Payables data reported for this period type.
Accounts Payables vs competitors
How ADRX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $5.6M USD | — | — | 608.1% | |
| LTM Mar 2026 | $4.81M USD | +99.3% | — | 6.7% | |
| LTM Mar 2026 | $4.66M USD | -479.9% | — | — | |
| FY2025 | $3.73M USD | — | — | 20.0% | |
| LTM Mar 2026 | $2.66M USD | +6.3% | -26.0% | 66.0% | |
| LTM Mar 2026 | $2.19M USD | -26.1% | -1.7% | 4.8% | |
| LTM Mar 2026 | $1.34M USD | -154.2% | — | 1.7% | |
| LTM Mar 2026 | $829K USD | -92.1% | +460.3% | 2.6% | |
| LTM Mar 2026 | €0 EUR | — | — | 0.0% | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding ADRX) | — | -59.1% | -1.7% | 5.8% | |
Competitors are the stored peer set for ADRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
ADARx Pharmaceuticals, Inc.
NASDAQ:ADRX
Intrinsic Alpha fair value
Locked
Current Price
$12.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.